{"id":258,"date":"2024-08-15T02:31:08","date_gmt":"2024-08-15T02:31:08","guid":{"rendered":"http:\/\/60.204.213.123\/wordpress\/?page_id=258"},"modified":"2024-12-02T03:25:39","modified_gmt":"2024-12-02T03:25:39","slug":"%e5%b7%b2%e5%85%ac%e5%b8%83%e7%9a%84%e8%82%9d%e7%99%8c%e8%82%bf%e7%98%a4%e7%aa%81%e5%8f%98%e6%8a%97%e5%8e%9f%e6%b8%85%e5%8d%95","status":"publish","type":"page","link":"https:\/\/www.guixiong.com.cn\/?page_id=258","title":{"rendered":"\u5df2\u516c\u5e03\u7684\u809d\u764c\u80bf\u7624\u7a81\u53d8\u6297\u539f\u6e05\u5355"},"content":{"rendered":"\n

\u4ee5\u4e0b\u662f\u76ee\u524d\u516c\u5e03\u7684\u809d\u764c\u80bf\u7624\u7a81\u53d8\u6297\u539f\u80bd\u6e05\u5355\uff0c\u8be5\u6e05\u5355\u5747\u652f\u6301\u5b9a\u5236\u751f\u4ea7 (\u5b9a\u5236\u54a8\u8be2\u8bf7\u626b\u63cf\u672c\u9875\u53f3\u4fa7\u8054\u7cfb\u4eba\u4e8c\u7ef4\u7801)\u3002\u53ef\u5b9a\u5236\u751f\u4ea7\uff1a<\/p>\n\n\n\n

    \n
  1. \u68c0\u6d4b\u6216\u5206\u9009\u6297\u539f\u7279\u5f02\u6027T\u7ec6\u80de\u7684\u6d41\u5f0f\u8bd5\u5242\u3001\u78c1\u73e0\u5206\u9009\u8bd5\u5242<\/li>\n\n\n\n
  2. \u6784\u5efa\u6297\u539f\u80bd\u548cMHC\u590d\u5408\u7269\uff0c\u7528\u4e8e\u5408\u6210\u4eba\u5de5\u5448\u9012\u7269\uff0c\u4ece\u800c\u523a\u6fc0T\u7ec6\u80de\u589e\u6b96<\/li>\n<\/ol>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
    \u6297\u539f\u86cb\u767d<\/th>\u6297\u539f\u80bd<\/th>\u5448\u9012\u6297\u539f\u7684HLA<\/th>\u9a8c\u8bc1\u6587\u732e<\/th>\n<\/tr>\n<\/thead>\n
    Receptor tyrosine-protein kinase erbB-2<\/td>IISAVVGIL<\/td>HLA-A2<\/td>Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007<\/td>\n<\/tr>\n
    HER2 receptor<\/td>TYLPTNASL<\/td>HLA-A24<\/td>Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007<\/td>\n<\/tr>\n
    Receptor tyrosine-protein kinase erbB-2<\/td>IISAVVGIL<\/td>HLA-A2<\/td>Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007<\/td>\n<\/tr>\n
    HER2 receptor<\/td>TYLPTNASL<\/td>HLA-A2<\/td>Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007<\/td>\n<\/tr>\n
    glypican 3<\/td>FVGEFFTDV<\/td>HLA-A*02:01<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>FVGEFFTDV<\/td>HLA-A*02:01<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    glypican 3<\/td>EYILSLEEL<\/td>HLA-A*24:02<\/td>Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017<\/td>\n<\/tr>\n
    Chromodomain-helicase-DNA-binding protein 3<\/td>AVMRWGMPL<\/td>HLA-A*02:01<\/td>Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018<\/td>\n<\/tr>\n
    MYO18A protein<\/td>VQLEEEYEV<\/td>HLA-A*02:01<\/td>Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018<\/td>\n<\/tr>\n
    Chromodomain-helicase-DNA-binding protein 3<\/td>AVMRWGMPP<\/td>HLA-A*02:01<\/td>Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018<\/td>\n<\/tr>\n
    Programmed cell death protein 7<\/td>VMLEGEQEA<\/td>HLA-A*02:01<\/td>Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018<\/td>\n<\/tr>\n
    Programmed cell death protein 7<\/td>VMLEGEQEE<\/td>HLA-A*02:01<\/td>Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018<\/td>\n<\/tr>\n
    Cytoplasmic dynein 1 heavy chain 1<\/td>TLFSALWAL<\/td>HLA-A*02:06<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    Cytoplasmic dynein 1 heavy chain 1<\/td>TLFSALWAL<\/td>HLA-A*02:06<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    hCG2043250, isoform CRA_b<\/td>WVMPVIPAL<\/td>HLA-A*02:06<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    hCG2043250, isoform CRA_b<\/td>WVMPVIPAL<\/td>HLA-A*02:06<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    E3 ubiquitin-protein ligase TRIM68<\/td>RLRKRNEYR<\/td>HLA-A*31:01<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    ATP-binding cassette sub-family A member 2<\/td>FLLPSGMAL<\/td>HLA-C*03:04<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    Sodium-independent sulfate anion transporter<\/td>LMRDHMPPV<\/td>HLA-A*02:03<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    Casein kinase I isoform alpha<\/td>YMYLRQLFHI<\/td>HLA-A*02:01<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    Casein kinase I isoform alpha<\/td>YMYLRQLFHI<\/td>HLA-A*02:01<\/td>High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+<\/sup>CD8<sup>+<\/sup> T cells. Gut 2021<\/td>\n<\/tr>\n
    Cytochrome b<\/td>SPWWNFGSLL<\/td>HLA-A*24:02<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Protein SSX2<\/td>ATLPPFMCNK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Glypican-3<\/td>LQSASMELK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Glypican-3<\/td>VVSQIIDKLK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>VRSLLRSHYR<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>FYVTETTFQK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>TTFQKNRLFFY<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>ALFSVLNYER<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>RAWRTFVLR<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>STLTDLQPY<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>KLFGVLRLK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>RTAQTQLSR<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Alpha-fetoprotein<\/td>ITVTKLSQK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Serpin B4<\/td>ALGMVLLGAK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Serpin I2<\/td>VLVNAIYFK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Serpin B3<\/td>GLVLSGVLHK<\/td>HLA-A*11:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Cancer\/testis antigen 1<\/td>AMPFATPMEA<\/td>HLA-A*02:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Telomerase reverse transcriptase<\/td>LLRSFFYV<\/td>HLA-A*02:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Alpha-fetoprotein<\/td>FLYAPTILLW<\/td>HLA-A*02:01<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Protein SSX7<\/td>KYEAMTKLGF<\/td>HLA-A*24:02<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Alpha-fetoprotein<\/td>KWVESIFLIF<\/td>HLA-A*24:02<\/td>Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021<\/td>\n<\/tr>\n
    Multiple inositol polyphosphate phosphatase 1<\/td>YPTVKQICKL<\/td>HLA-B*07:02<\/td>Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci 2022<\/td>\n<\/tr>\n
    Mitochondrial 2-oxodicarboxylate carrier<\/td>LLMMTIASV<\/td>HLA-A*02:07<\/td>Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci 2022<\/td>\n<\/tr>\n
    Cell adhesion molecule 2<\/td>TLMTATVTT<\/td>HLA-A*02:07<\/td>Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

    Views: 6<\/p>","protected":false},"excerpt":{"rendered":"

    \u4ee5\u4e0b\u662f\u76ee\u524d\u516c\u5e03\u7684\u809d\u764c\u80bf\u7624\u7a81\u53d8\u6297\u539f\u80bd\u6e05\u5355\uff0c\u8be5\u6e05\u5355\u5747\u652f\u6301\u5b9a\u5236\u751f\u4ea7 (\u5b9a\u5236\u54a8\u8be2\u8bf7\u626b\u63cf\u672c\u9875\u53f3\u4fa7\u8054\u7cfb\u4eba\u4e8c\u7ef4\u7801)\u3002\u53ef\u5b9a\u5236\u751f…<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-258","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=258"}],"version-history":[{"count":2,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/258\/revisions"}],"predecessor-version":[{"id":624,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/258\/revisions\/624"}],"wp:attachment":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}